TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10811665

Group type: EXPERIMENTAL
Intervention: Protocol-based systemic and intrathecal chemotherapy + CNS irradiation (for 36 patients)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CNS disease (CSF+/Mass)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: M2 or M3 marrow status
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: LDH levels greater than 500 IU/L
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Isolated CNPs
Number of subjects: 49
Study: 8831651

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 138
Study: 1482143

Group type: COMPARATOR
Intervention: 400 mg of fleroxacin alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg of fleroxacin with 1 g of sucralfate every 6 h starting 24 h before and continuing for 48 h after fleroxacin treatment
Number of subjects: 20
Study: 4067973

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 155

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Unilateral myringotomy and grommet insertion
Number of subjects: 155
Study: 31536984

Group type: EXPERIMENTAL
Intervention: Dumbbell exercise (6-pound dumbbells on non-dialysis days for 3 months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (squeezed rubber balls)
Number of subjects: 86
Study: 30766716

Group type: EXPERIMENTAL
Intervention: Depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (NET‐EN)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Nonuser controls
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH) level >/= 25.8 mIU/mL
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Interaction between FSH and BMI
Number of subjects: 395
Study: 27539113

Group type: EXPERIMENTAL
Intervention: Atlantic diet (AD group)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Control diet (C group)
Number of subjects: 715
Study: 24803033

Group type: EXPERIMENTAL
Intervention: Sodium butyrate 1 g, 2 g, or 4 g daily
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 22030709

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=13)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy (CBT) (n=13)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Matched-healthy controls (n=36)
Number of subjects: 38
Study: 20215520

Group type: EXPERIMENTAL
Intervention: Pazopanib therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline CAF levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline CAF signature (hepatocyte growth factor and IL-12)
Number of subjects: 33
Study: 19033112

Group type: EXPERIMENTAL
Intervention: 3DCRT at the total dose of 66 to 70 Gy in 33 to 35 fractions
Number of subjects: 68

Group type: COMPARATOR
Intervention: Stereotactic radiotherapy (SRT) at the dose of 20 Gy in 4 fractions after 60 Gy 3DCRT
Number of subjects: 68
Study: 15820236

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 23
Study: 12839580

Group type: EXPERIMENTAL
Intervention: Sunscreens with varying ultraviolet A protective capability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunscreens with constant ultraviolet B protection
Number of subjects: 0
Study: 10372727

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 100 mg DHEA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8559537

Group type: EXPERIMENTAL
Intervention: Cystopexy alone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cystopexy with posterior pubourethral ligaments plication
Number of subjects: 102
Study: 1866674

Group type: EXPERIMENTAL
Intervention: Reperitonealization of the lesser curve (45 patients)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (51 patients)
Number of subjects: 96
Study: 7065351

Group type: EXPERIMENTAL
Intervention: Drainage through a standard Penrose or Chaffin‐Pratt sump tube
Number of subjects: 300

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 300
Study: 31503307

Group type: EXPERIMENTAL
Intervention: Methotrexate, 25 mg weekly (n=107)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Mycophenolate mofetil, 3 g daily (n=109)
Number of subjects: 216
Study: 28285187

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25885521

Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx 100 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx 200 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx 400 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx (all doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx
Number of subjects: 51
Study: 23539083

Group type: COMPARATOR
Intervention: Aero helmet (AERO)
Number of subjects: 10
Study: 21386067

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study: 19744007

Group type: EXPERIMENTAL
Intervention: Water-soluble tocofersolan (1200 IU for adults, 100 IU/kg for children)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Water-soluble tocofersolan (100 IU/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study: 17184645

Group type: EXPERIMENTAL
Intervention: Medium-dose aspirin (325 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg)
Number of subjects: 63
Study: 15100522

Group type: EXPERIMENTAL
Intervention: Sodium phosphate tablets
Number of subjects: 97

Group type: COMPARATOR
Intervention: Polyethylene glycol solution
Number of subjects: 97
Study: 15235337

Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure (CRP)
Number of subjects: 9
Study: 10090295

Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 557

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 557
Study: 7480125

Group type: COMPARATOR
Intervention: Without SAFOs
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right SAFO
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left SAFO
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bilateral SAFOs
Number of subjects: 39
Study: 2123632

Group type: EXPERIMENTAL
Intervention: Epoetin beta (Marogen Sterile Powder, Chugai‐Upjohn, Inc.) for an average of 18 months
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (no epoetin beta therapy)
Number of subjects: 187
Study: 7192884

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 9 mEq/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no sodium bicarbonate)
Number of subjects: 50
Study: 31999500

Group type: EXPERIMENTAL
Intervention: Bauhinia forficata Link tincture (BFLT) 23.2 mg/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine 0.12%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Growth control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline (48h maturation biofilm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ethanol 81.20 g/mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 60
Study: 30643228

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous endotoxin
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Baseline activity of transcription factors (TFs) related to inflammation (NF-kB) and sympathetic activation (CREB)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Baseline activity of glucocorticoid receptor (GR) related TFs
Number of subjects: 115
Study: 27592635

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy targeting intolerance of uncertainty (CBT‐IU)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 63
Study: 25515279

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band surgery
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conservatively treated (dietician and very low calorie diet)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Weight loss (both interventions)
Number of subjects: 57
Study: 24699237

Group type: EXPERIMENTAL
Intervention: 6-month internet-delivered physical activity behavioral intervention
Number of subjects: 82
Study: 22971184

Group type: EXPERIMENTAL
Intervention: One-piece IOL implantation in CACG group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Three-piece IOL implantation in CACG group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: One-piece IOL group using SRK/T formula
Number of subjects: 93
Study: 19943398

Group type: EXPERIMENTAL
Intervention: Working on 2 character strengths
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Working on 1 character strength and 1 relative weakness
Number of subjects: 76

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 76
Study: 17690310

Group type: EXPERIMENTAL
Intervention: Hemicraniectomy (surgical intervention)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conservative therapy (control)
Number of subjects: 32
Study: 15352909

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin estimation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Erythrocyte sedimentation rate > 10 mm
Number of subjects: 73

Group type: COMPARATOR
Intervention: C-reactive protein > 6 mg/L
Number of subjects: 73

Group type: COMPARATOR
Intervention: Combination of erythrocyte sedimentation rate and C-reactive protein
Number of subjects: 73
Study: 12452386

Group type: EXPERIMENTAL
Intervention: White wine (12.5% alcohol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Juice (matched control)
Number of subjects: 10
Study: 9878986

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 10948

Group type: EXPERIMENTAL
Intervention: Combination of tirofiban and heparin
Number of subjects: 10948

Group type: EXPERIMENTAL
Intervention: Low dose lamifiban
Number of subjects: 10948

Group type: EXPERIMENTAL
Intervention: High dose lamifiban
Number of subjects: 10948

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 10948
Study: 9005131

Group type: EXPERIMENTAL
Intervention: General anaesthesia (Group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Peridural anaesthesia (Group B)
Number of subjects: 46
Study: 30782765

Group type: EXPERIMENTAL
Intervention: Informed shared decision-making programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28984076

Group type: EXPERIMENTAL
Intervention: Family-Based Behavioral Treatment (FBT)
Number of subjects: 241
Study: 26316194

Group type: EXPERIMENTAL
Intervention: Internet CBT adjunctive to specialized headache treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Specialized headache treatment alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups (Internet CBT and control)
Number of subjects: 83
Study: 23746673

Group type: EXPERIMENTAL
Intervention: Immediate total provisional prosthesis on temporary immediate implants (test group, 12 patients)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (4 patients)
Number of subjects: 16
Study: 20213220

Group type: EXPERIMENTAL
Intervention: Thalidomide-based combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide-based combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib-based combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational agents
Number of subjects: 0
Study: 17217360

Group type: EXPERIMENTAL
Intervention: Decision aid (24-page booklet, 30-minute audio-CD, and worksheet) in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only with standard counselling
Number of subjects: 0
Study: 16373258

Group type: EXPERIMENTAL
Intervention: DHEA (30 mg/20 mg daily for <45/≥46 years)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups during active treatment
Number of subjects: 41
Study: 12027839

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0% with 5 microg/kg/h remifentanil)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol (3 mg/kg/h with 5 microg/kg/h remifentanil)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 10204127

Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg i.v. single dose)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Cephradine (1 g i.v. + metronidazole (1 g rectally) with two further doses of cephradine and metronidazole
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 272
Study: 7774110

Group type: EXPERIMENTAL
Intervention: Fish oil (1.7 gm eicosapentaenoic acid and 1.1 gm docosahexaenoic acid/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 2338403

Group type: EXPERIMENTAL
Intervention: Piracetam (170 mg/kg for acute treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piracetam (140 mg/kg/day for chronic treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7437777

Group type: EXPERIMENTAL
Intervention: Arterial reconstruction
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unilateral nephrectomy
Number of subjects: 26
Study: 31676314

Group type: EXPERIMENTAL
Intervention: Awake craniotomy (AC)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Craniotomy under general anesthesia (GA)
Number of subjects: 246
Study: 30088321

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review and patient interview upon admission (intervention ED)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review and patient interview upon admission, medication review during inpatient stay, and medication report and patient counselling at discharge (intervention STAY)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 600
Study: 28771093

Group type: COMPARATOR
Intervention: Placebo control (edible cannabis lollipop with no active THC)
Number of subjects: 20
Study: 25603725

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Beractant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (preterm infants without RDS)
Number of subjects: 30
Study: 23559412

Group type: EXPERIMENTAL
Intervention: Strength training with whole-body vibration
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Strength training without whole-body vibration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 21150933

Group type: EXPERIMENTAL
Intervention: Office pulse pressure (PP)
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Ambulatory pulse pressure (PP)
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Office and ambulatory pulse pressure (PP)
Number of subjects: 4449
Study: 19634965

Group type: EXPERIMENTAL
Intervention: Higher baseline meaning/peace
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Increase in meaning/peace over 6 months
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Baseline faith
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Increase in meaning/peace
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Increase in faith
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Meaning/peace and faith interaction
Number of subjects: 583
Study: 17936154

Group type: EXPERIMENTAL
Intervention: KW-3902 2.5 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: KW-3902 15 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: KW-3902 30 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: KW-3902 60 mg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: KW-3902 (all doses)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: KW-3902 10 mg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 15378139

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin daily plus usual therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual therapy (control group)
Number of subjects: 205
Study: 12003478

Group type: EXPERIMENTAL
Intervention: Negative past experiences (unfavorable implications)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Positive past experiences (flattering implications)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High self-esteem participants
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low self-esteem participants
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Frequency of rehearsal and ease of recall
Number of subjects: 3
Study: 9652440

Group type: EXPERIMENTAL
Intervention: Isogenic hemolysin-deficient mutant (35000HP-RSM1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent strain (35000HP)
Number of subjects: 0
Study: 7808646

Group type: EXPERIMENTAL
Intervention: Patients at risk for ARDS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 24
Study: 2628706

Group type: EXPERIMENTAL
Intervention: 0.05% metronidazole solution (MD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo solution (MDP)
Number of subjects: 12
Study: 1104059

Group type: EXPERIMENTAL
Intervention: Sodium valproate 1200 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31915172

Group type: EXPERIMENTAL
Intervention: Vitamin D and/or fish oil supplementation for 5 years
Number of subjects: 25871

Group type: COMPARATOR
Intervention: Control group (no vitamin D and/or fish oil supplementation)
Number of subjects: 25871
Study: 31267113

Group type: EXPERIMENTAL
Intervention: Randomized 5' UTRs
Number of subjects: 280000

Group type: EXPERIMENTAL
Intervention: Chemically modified RNA
Number of subjects: 280000

Group type: EXPERIMENTAL
Intervention: Truncated human 5' UTRs
Number of subjects: 280000

Group type: EXPERIMENTAL
Intervention: Naturally occurring variants
Number of subjects: 280000

Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants (SNVs)
Number of subjects: 280000
Study: 27651026

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.5, 1, and 3 μg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Buprenorphine plus milnacipran (25 and 50 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Milnacipran (25 or 50 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Milnacipran (50 mg)
Number of subjects: 11
Study: 25322262

Group type: EXPERIMENTAL
Intervention: Aerobic and resistance training (50min, moderate intensity, twice a week for 6 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sedentary activities (Control group)
Number of subjects: 49
Study: 24346592

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Anterior cervical corpectomy and fusion (ACCF)
Number of subjects: 61
Study: 22749178

Group type: EXPERIMENTAL
Intervention: 379 mg of Green Tea Extract (GTE)
Number of subjects: 56
Study: 19339758

Group type: EXPERIMENTAL
Intervention: Dual-task cognitive-motor intervention (CGI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo treatment (walking with simple music)
Number of subjects: 13
Study: 17728106

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 86
Study: 15850857

Group type: EXPERIMENTAL
Intervention: Culturally targeted education and free testing delivered by a Native Hawaiian physician and CRC survivor, including FOBT demo and multiple reminder calls.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Culturally targeted presentation, free FOBT, and reminder call delivered by a non-Hawaiian nurse.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both arms received similar and significant gains in CRC knowledge, attitudes, intent, and self-efficacy.
Number of subjects: 121
Study: 12539939

Group type: EXPERIMENTAL
Intervention: Steel reconstruction plates
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Herbert cannulated bone screw
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (clavicles without osteosynthesis material)
Number of subjects: 14
Study: 10223941

Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg oral dose following a high-fat breakfast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rifapentine 600 mg oral dose during fasting
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifapentine with high-fat breakfast
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifapentine
Number of subjects: 16
Study: 8582465

Group type: EXPERIMENTAL
Intervention: 5 mg metoprolol plus 20 mg denopamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg metoprolol plus denopamine placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2151407

Group type: EXPERIMENTAL
Intervention: AH23848 70 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin 300 mg plus dipyridamole 75 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 386063

Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31634518

Group type: EXPERIMENTAL
Intervention: Social inclusion (acceptance) condition
Number of subjects: 80

Group type: COMPARATOR
Intervention: Social exclusion (rejection) condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maternal acceptance-rejection perceptions
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mothers' use of food to regulate children's distress
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Children's own BMI
Number of subjects: 80
Study: 29563108

Group type: EXPERIMENTAL
Intervention: blisibimod (200 mg weekly)
Number of subjects: 442

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 442
Study: 26893497

Group type: EXPERIMENTAL
Intervention: Flecainide + Metoprolol (n = 80)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Flecainide only (n = 72)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Metoprolol only (n = 21)
Number of subjects: 173